Rigel Pharmaceuticals Unveils Inducement Grants for New Employees #United_States #South_San_Francisco #Rigel_Pharmaceuticals #Inducement_Grants #Nasdaq_RIGL
0
0
0
0
Hashtag
#Rigel_Pharmaceuticals
Advertisement · 728 × 90
Rigel's Final ARROW Clinical Trial Data Shows Promising Outcomes for GAVRETO® in RET+ NSCLC Patients #United_States #South_San_Francisco #Rigel_Pharmaceuticals #GAVRETO #RET_fusion-positive
0
0
0
0
Rigel Pharmaceuticals Reports Impressive Financial Results for 2025 with Robust Growth and A Promising Future #USA #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #GAVRETO
0
0
0
0
Rigel Pharmaceuticals Welcomes Michael P. Miller to Board of Directors #USA #South_San_Francisco #Rigel_Pharmaceuticals #Biotech_Leadership #Mike_Miller
0
0
0
0
Rigel Pharmaceuticals Announces Positive 2025 Revenues and 2026 Projections #United_States #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #GAVRETO
0
0
0
0
Rigel Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) #United_States #biotechnology #South_San_Francisco #Rigel_Pharmaceuticals #Inducement_Grants
0
0
0
0
Rigel Pharmaceuticals Releases New Findings on R289 for Lower-Risk MDS at ASH 2025 #United_States #South_San_Francisco #Rigel_Pharmaceuticals #R289 #MDS
0
0
0
0
Rigel Pharmaceuticals to Showcase Innovations at Key Healthcare Conference #United_States #South_San_Francisco #Health_Innovations #Rigel_Pharmaceuticals #Nasdaq_RIGL
0
0
0
0
Rigel Pharmaceuticals Releases Comprehensive Five-Year Findings on REZLIDHIA® for R/R mIDH1 AML Treatment #United_States #South_San_Francisco #Rigel_Pharmaceuticals #REZLIDHIA #mIDH1_AML
0
0
0
0
Rigel Pharmaceuticals to Showcase Innovations at Jefferies Global Healthcare Conference in London #United_States #Cancer_Research #South_San_Francisco #Rigel_Pharmaceuticals #Hematologic_Disorders
0
0
0
0
Rigel Pharmaceuticals Announces Robust Q3 2025 Financial Results and Strategic Outlook #United_States #South_San_Francisco #Rigel_Pharmaceuticals #R289 #TAVALISSE
0
0
0
0
Rigel Pharmaceuticals to Present Key Data at ASH Annual Meeting 2025 Focused on Innovative Hematologic Therapies #United_States #South_San_Francisco #Rigel_Pharmaceuticals #R289 #mIDH1_AML
0
0
0
0
Rigel Pharmaceuticals Enrolls First Patient in R289 Expansion Study for Lower-Risk MDS #United_States #South_San_Francisco #Rigel_Pharmaceuticals #R289 #MDS
0
0
0
0
Rigel Pharmaceuticals Announces Employee Inducement Grants Under NASDAQ Rule 5635(c)(4) #USA #stock_options #South_San_Francisco #Rigel_Pharmaceuticals #restricted_stock
0
0
0
0
Rigel Pharmaceuticals Announces Strong Financial Growth and Clinical Progress in Q2 2025 #United_States #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #GAVRETO
0
0
0
0
Rigel Pharmaceuticals Unveils Inducement Grants Aligned with NASDAQ Listing Rules #USA #NASDAQ #South_San_Francisco #Rigel_Pharmaceuticals #Inducement_Grants
0
0
0
0
Rigel Pharmaceuticals to Showcase Innovations at Jefferies Global Healthcare Conference #United_States #New_York #biotechnology #Rigel_Pharmaceuticals #Jefferies_Conference
0
0
0
0
Rigel Pharmaceuticals to Present Key Data at ASCO and EHA 2025 Conferences #United_States #South_San_Francisco #Rigel_Pharmaceuticals #REZLIDHIA #GAVRETO
0
0
0
0
Rigel Pharmaceuticals Reports Impressive First Quarter Performance and Strategic Updates #USA #South_San_Francisco #Rigel_Pharmaceuticals #R289 #TAVALISSE
0
0
0
0
Rigel Pharmaceuticals Unveils Inducement Grants Under NASDAQ Rule 5635(c)(4) #United_States #stock_options #South_San_Francisco #Rigel_Pharmaceuticals #Inducement_Grants
0
0
0
0
Rigel Pharmaceuticals Settles Patent Dispute Over TAVALISSE® with Annora Pharma #United_States #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #Annora_Pharma
0
0
0
0
Rigel Pharmaceuticals Welcomes Dr. Mark W. Frohlich to its Board of Directors #USA #oncology #South_San_Francisco #Rigel_Pharmaceuticals #Mark_Frohlich
0
0
0
0
Rigel Pharmaceuticals Releases Impressive Q4 and Full Year 2024 Financial Results Amidst Strong Business Expansion #USA #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #REZLIDHIA
0
0
0
0
Rigel's Fostamatinib Undergoing Phase 1 Trials for Sickle Cell Disease Treatment #None #Bethesda #Rigel_Pharmaceuticals #sickle_cell_disease #Fostamatinib
0
0
0
0
Rigel Pharmaceuticals Reflects on 2024 Milestones and Sets Ambitious Goals for 2025 #USA #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #REZLIDHIA
0
0
0
0
Rigel Pharmaceuticals Achieves FDA Orphan Drug Designation for R289 in Treating MDS #United_States #South_San_Francisco #Rigel_Pharmaceuticals #R289 #MDS
0
0
0
0
Rigel Pharmaceuticals Announces Participation in J.P. Morgan Healthcare Conference 2025 #United_States #San_Francisco #Cancer_Treatments #Healthcare_Conference #Rigel_Pharmaceuticals
0
0
0
0
Rigel Pharmaceuticals Grants Inducement Stock Options to New Employees Under NASDAQ Rule #United_States #stock_options #South_San_Francisco #Rigel_Pharmaceuticals #RIGL
0
0
0
0
Rigel Pharmaceuticals Presents Promising Phase 1b Study Results of R289 for Lower-Risk MDS at ASH 2024 #United_States #San_Diego #Rigel_Pharmaceuticals #R289 #ASH_2024
0
0
0
0
Rigel Pharmaceuticals Receives FDA Fast Track Designation for R289 in Treating Lower-Risk MDS #United_States #South_San_Francisco #Rigel_Pharmaceuticals #R289 #MDS
0
0
0
0